Defining the Role of mTOR in Cancer

Cancer Cell

Volumn 12, Issue 1, 2007, Pages 9-22

  Guertin, David A ^a,b   Sabatini, David M ^a,b,c  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AP 23573; CISPLATIN; EVEROLIMUS; GEFITINIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PROTEIN KINASE B; RAPAMYCIN; TAMOXIFEN; TEMSIROLIMUS;

ANGIOGENESIS; CANCER; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONGENITAL TUMOR; ENZYME ACTIVATION; EVOLUTION; FEEDBACK SYSTEM; HUMAN; MANTLE CELL LYMPHOMA; MUTATION; NONHUMAN; ONCOLOGY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 34347220473     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2007.05.008     Document Type: Review

References (138)

1. Ackah E., Yu J., Zoellner S., Iwakiri Y., Skurk C., Shibata R., Ouchi N., Easton R.M., Galasso G., Birnbaum M.J., et al. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J. Clin. Invest. 115 (2005) 2119-2127
2. Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., and Hemmings B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15 (1996) 6541-6551
3. Ali S.M., and Sabatini D.M. Structure of S6K1 determines if raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site. J. Biol. Chem. 280 (2005) 19445-19448
4. Baba M., Hong S.B., Sharma N., Warren M.B., Nickerson M.L., Iwamatsu A., Esposito D., Gillette W.K., Hopkins III R.F., Hartley J.L., et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc. Natl. Acad. Sci. USA 103 (2006) 15552-15557
5. Bachmann R.A., Kim J.H., Wu A.L., Park I.H., and Chen J. A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1. J. Biol. Chem. 281 (2006) 7357-7363
6. Ballif B.A., Roux P.P., Gerber S.A., MacKeigan J.P., Blenis J., and Gygi S.P. Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc. Natl. Acad. Sci. USA 102 (2005) 667-672
7. Bernardi R., Guernah I., Jin D., Grisendi S., Alimonti A., Teruya-Feldstein J., Cordon-Cardo C., Simon M.C., Rafii S., and Pandolfi P.P. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442 (2006) 779-785
8. Biondi R.M., Kieloch A., Currie R.A., Deak M., and Alessi D.R. The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J. 20 (2001) 4380-4390
9. Brognard J., Sierecki E., Gao T., and Newton A.C. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol. Cell 25 (2007) 917-931
10. Buerger C., DeVries B., and Stambolic V. Localization of Rheb to the endomembrane is critical for its signaling function. Biochem. Biophys. Res. Commun. 344 (2006) 869-880
11. Campistol J.M., Gutierrez-Dalmau A., and Torregrosa J.V. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 77 (2004) 760-762
12. Chen M.L., Xu P.Z., Peng X.D., Chen W.S., Guzman G., Yang X., Di Cristofano A., Pandolfi P.P., and Hay N. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev. 20 (2006) 1569-1574
13. Chiang G.G., and Abraham R.T. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J. Biol. Chem. 280 (2005) 25485-25490
14. Choi J.H., Bertram P.G., Drenan R., Carvalho J., Zhou H.H., and Zheng X.F. The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase. EMBO Rep. 3 (2002) 988-994
15. Collins B.J., Deak M., Arthur J.S., Armit L.J., and Alessi D.R. In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. EMBO J. 22 (2003) 4202-4211
16. Corradetti M.N., Inoki K., Bardeesy N., DePinho R.A., and Guan K.L. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 18 (2004) 1533-1538
17. Crino P.B., Nathanson K.L., and Henske E.P. The tuberous sclerosis complex. N. Engl. J. Med. 355 (2006) 1345-1356
18. Desai B.N., Myers B.R., and Schreiber S.L. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc. Natl. Acad. Sci. USA 99 (2002) 4319-4324
19. Di Cristofano A., Pesce B., Cordon-Cardo C., and Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19 (1998) 348-355
20. Dong J., and Pan D. Tsc2 is not a critical target of Akt during normal Drosophila development. Genes Dev. 18 (2004) 2479-2484
21. Dorrello N.V., Peschiaroli A., Guardavaccaro D., Colburn N.H., Sherman N.E., and Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314 (2006) 467-471
22. Drenan R.M., Liu X., Bertram P.G., and Zheng X.F. FKBP12-rapamycin-associated protein or mammalian target of rapamycin (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi apparatus. J. Biol. Chem. 279 (2004) 772-778
23. Easton J.B., and Houghton P.J. mTOR and cancer therapy. Oncogene 25 (2006) 6436-6446
24. Eng C. PTEN: one gene, many syndromes. Hum. Mutat. 22 (2003) 183-198
25. Faivre S., Kroemer G., and Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5 (2006) 671-688
26. Fan Q.W., and Weiss W.A. Isoform specific inhibitors of PI3 kinase in glioma. Cell Cycle 5 (2006) 2301-2305
27. Findlay G.M., Yan L., Procter J., Mieulet V., and Lamb R.F. A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling. Biochem. J. 430 (2007) 13-20
28. Franz D.N., Leonard J., Tudor C., Chuck G., Care M., Sethuraman G., Dinopoulos A., Thomas G., and Crone K.R. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 59 (2006) 490-498
29. Frias M.A., Thoreen C.C., Jaffe J.D., Schroder W., Sculley T., Carr S.A., and Sabatini D.M. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol. 16 (2006) 1865-1870
30. Fumarola C., La Monica S., Alfieri R.R., Borra E., and Guidotti G.G. Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis. Cell Death Differ. 12 (2005) 1344-1357
31. Furuyama T., Kitayama K., Shimoda Y., Ogawa M., Sone K., Yoshida-Araki K., Hisatsune H., Nishikawa S., Nakayama K., Ikeda K., et al. Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J. Biol. Chem. 279 (2004) 34741-34749
32. Gangloff Y.G., Mueller M., Dann S.G., Svoboda P., Sticker M., Spetz J.F., Um S.H., Brown E.J., Cereghini S., Thomas G., and Kozma S.C. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell. Biol. 24 (2004) 9508-9516
33. Gao T., Furnari F., and Newton A.C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell 18 (2005) 13-24
34. Ghosh S., Tergaonkar V., Rothlin C.V., Correa R.G., Bottero V., Bist P., Verma I.M., and Hunter T. Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival. Cancer Cell 10 (2006) 215-226
35. Granville C.A., Memmott R.M., Gills J.J., and Dennis P.A. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin. Cancer Res. 12 (2006) 679-689
36. Granville C.A., Warfel N., Tsurutani J., Hollander M.C., Robertson M., Fox S.D., Veenstra T.D., Issaq H.J., Linnoila R.I., and Dennis P.A. Identification of a Highly Effective Rapamycin Schedule that Markedly Reduces the Size, Multiplicity, and Phenotypic Progression of Tobacco Carcinogen-Induced Murine Lung Tumors. Clin. Cancer Res. 13 (2007) 2281-2289
37. Greer E.L., and Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24 (2005) 7410-7425
38. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8 (2002) 128-135
39. Guertin D.A., Guntur K.V., Bell G.W., Thoreen C.C., and Sabatini D.M. Functional genomics identifies TOR-regulated genes that control growth and division. Curr. Biol. 16 (2006) 958-970
40. Guertin D.A., and Sabatini D.M. An expanding role for mTOR in cancer. Trends Mol. Med. 11 (2005) 353-361
41. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., Brown M., Fitzgerald K.J., and Sabatini D.M. Ablation in Mice of the mTORC Components raptor, rictor, or mLST8 Reveals that mTORC2 Is Required for Signaling to Akt-FOXO and PKCalpha, but Not S6K1. Dev. Cell 11 (2006) 859-871
42. Haar E.V., Lee S.I., Bandhakavi S., Griffin T.J., and Kim D.H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 9 (2007) 316-323
43. Hanada M., Feng J., and Hemmings B.A. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim. Biophys. Acta 1697 (2004) 3-16
44. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., Tokunaga C., Avruch J., and Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR) mediates TOR Action. Cell 110 (2002) 177-189
45. Hartmann C., Johnk L., Kitange G., Wu Y., Ashworth L.K., Jenkins R.B., and Louis D.N. Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Res. 62 (2002) 4100-4108
46. Hietakangas V., and Cohen S.M. Re-evaluating AKT regulation: role of TOR complex 2 in tissue growth. Genes Dev. 21 (2007) 632-637
47. Hipp S., Ringshausen I., Oelsner M., Bogner C., Peschel C., and Decker T. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 90 (2005) 1433-1434
48. Holz M.K., Ballif B.A., Gygi S.P., and Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123 (2005) 569-580
49. Holz M.K., and Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem. 280 (2005) 26089-26093
50. Hosaka T., Biggs III W.H., Tieu D., Boyer A.D., Varki N.M., Cavenee W.K., and Arden K.C. Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc. Natl. Acad. Sci. USA 101 (2004) 2975-2980
51. Hresko R.C., and Mueckler M. mTOR/RICTOR is the Ser473 kinase for Akt/PKB in 3T3-L1 adipocytes. J. Biol. Chem. 280 (2005) 40406-40416
52. Hsu Y.C., Chern J.J., Cai Y., Liu M., and Choi K.W. Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 445 (2007) 785-788
53. Huang B., and Porter G. Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis. Acta Pharmacol. Sin. 26 (2005) 1253-1258
54. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., Giaccia A.J., and Abraham R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22 (2002) 7004-7014
55. Huffman T.A., Mothe-Satney I., and Lawrence Jr. J.C. Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc. Natl. Acad. Sci. USA 99 (2002) 1047-1052
56. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 12 (2002) 12
57. Inoki K., Ouyang H., Zhu T., Lindvall C., Wang Y., Zhang X., Yang Q., Bennett C., Harada Y., Stankunas K., et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126 (2006) 955-968
58. Inoki K., Zhu T., and Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 (2003) 577-590
59. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., Huang Q., Qin J., and Su B. SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity. Cell 127 (2006) 125-137
60. Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A., and Hall M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6 (2004) 1122-1128
61. Jaeschke A., Hartkamp J., Saitoh M., Roworth W., Nobukuni T., Hodges A., Sampson J., Thomas G., and Lamb R. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J. Cell Biol. 159 (2002) 217-224
62. Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., and Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. USA 102 (2005) 8573-8578
63. Kim D.-H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., Tempst P., and Sabatini D.M. mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery. Cell 110 (2002) 163-175
64. Kim D.-H., Sarbassov D.D., Ali S.M., Latek R.R., Guntur K.V., Erdjument-Bromage H., Tempst P., and Sabatini D.M. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 11 (2003) 895-904
65. Kim J.E., and Chen J. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc. Natl. Acad. Sci. USA 97 (2000) 14340-14345
66. Kim W.Y., and Kaelin W.G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22 (2004) 4991-5004
67. Kovacina K.S., Park G.Y., Bae S.S., Guzzetta A.W., Schaefer E., Birnbaum M.J., and Roth R.A. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J. Biol. Chem. 278 (2003) 10189-10194
68. Kwiatkowski D.J., Zhang H., Bandura J.L., Heiberger K.M., Glogauer M., el-Hashemite N., and Onda H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11 (2002) 525-534
69. Lee S., Comer F.I., Sasaki A., McLeod I.X., Duong Y., Okumura K., Yates III J.R., Parent C.A., and Firtel R.A. TOR Complex 2 Integrates Cell Movement during Chemotaxis and Signal Relay in Dictyostelium. Mol. Biol. Cell 16 (2005) 4572-4583
70. Lee S., Parent C.A., Insall R., and Firtel R.A. A novel Ras-interacting protein required for chemotaxis and cyclic adenosine monophosphate signal relay in Dictyostelium. Mol. Biol. Cell 10 (1999) 2829-2845
71. Li W., Petrimpol M., Molle K.D., Hall M.N., Battegay E.J., and Humar R. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ. Res. 100 (2007) 79-87
72. Liang J., Shao S.H., Xu Z.X., Hennessy B., Ding Z., Larrea M., Kondo S., Dumont D.J., Gutterman J.U., Walker C.L., et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat. Cell Biol. 9 (2007) 218-224
73. Liu X., and Zheng X.F. Endoplasmic reticulum and Golgi localization sequences for Mammalian target of rapamycin. Mol. Biol. Cell 18 (2007) 1073-1082
74. Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., Bonenfant D., Oppliger W., Jenoe P., and Hall M.N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10 (2002) 457-468
75. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., and Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121 (2005) 179-193
76. Ma L., Teruya-Feldstein J., Behrendt N., Chen Z., Noda T., Hino O., Cordon-Cardo C., and Pandolfi P.P. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev. 19 (2005) 1779-1786
77. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10 (2004) 594-601
78. Manning B.D. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167 (2004) 399-403
79. Manning B.D., Logsdon M.N., Lipovsky A.I., Abbott D., Kwiatkowski D.J., and Cantley L.C. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev. 19 (2005) 1773-1778
80. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., and Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10 (2002) 151-162
81. McManus E.J., Collins B.J., Ashby P.R., Prescott A.R., Murray-Tait V., Armit L.J., Arthur J.S., and Alessi D.R. The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation. EMBO J. 23 (2004) 2071-2082
82. Murakami M., Ichisaka T., Maeda M., Oshiro N., Hara K., Edenhofer F., Kiyama H., Yonezawa K., and Yamanaka S. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell. Biol. 24 (2004) 6710-6718
83. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J.J., Wu H., and Sawyers C.L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98 (2001) 10314-10319
84. Nobukuni T., Joaquin M., Roccio M., Dann S.G., Kim S.Y., Gulati P., Byfield M.P., Backer J.M., Natt F., Bos J.L., et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc. Natl. Acad. Sci. USA 102 (2005) 14238-14243
85. Paik J.H., Kollipara R., Chu G., Ji H., Xiao Y., Ding Z., Miao L., Tothova Z., Horner J.W., Carrasco D.R., et al. FoxOs Are Lineage-Restricted Redundant Tumor Suppressors and Regulate Endothelial Cell Homeostasis. Cell 128 (2007) 309-323
86. Pearce L.R., Huang X., Boudeau J., Pawlowski R., Wullschleger S., Deak M., Ibrahim A., Gourlay R., Magnuson M.A., and Alessi D.R. Identification of Protor as a novel Rictor-binding component of mTOR-complex-2. Biochem. J. (2007) 10.1042/BJ20070540 In press. Published online April 27, 2007
87. Phung T.L., Ziv K., Dabydeen D., Eyiah-Mensah G., Riveros M., Perruzzi C., Sun J., Monahan-Earley R.A., Shiojima I., Nagy J.A., et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10 (2006) 159-170
88. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., Cordon-Cardo C., Catoretti G., Fisher P.E., and Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA 96 (1999) 1563-1568
89. Podsypanina K., Lee R.T., Politis C., Hennessy I., Crane A., Puc J., Neshat M., Wang H., Yang L., Gibbons J., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. USA 98 (2001) 10320-10325
90. Potente M., Urbich C., Sasaki K., Hofmann W.K., Heeschen C., Aicher A., Kollipara R., DePinho R.A., Zeiher A.M., and Dimmeler S. Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J. Clin. Invest. 115 (2005) 2382-2392
91. Recher C., Dos Santos C., Demur C., and Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 4 (2005) 1540-1549
92. Reiling J.H., and Sabatini D.M. Stress and mTORture signaling. Oncogene 25 (2006) 6373-6383
93. Roux P.P., Ballif B.A., Anjum R., Gygi S.P., and Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. USA 101 (2004) 13489-13494
94. Rudelius M., Pittaluga S., Nishizuka S., Pham T.H., Fend F., Jaffe E.S., Quintanilla-Martinez L., and Raffeld M. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 108 (2006) 1668-1676
95. Sabatini D.M., Barrow R.K., Blackshaw S., Burnett P.E., Lai M.M., Field M.E., Bahr B.A., Kirsch J., Betz H., and Snyder S.H. Interaction of RAFT1 with gephyrin required for rapamycin-sensitive signaling. Science 284 (1999) 1161-1164
96. Samuels Y., Diaz Jr. L.A., Schmidt-Kittler O., Cummins J.M., Delong L., Cheong I., Rago C., Huso D.L., Lengauer C., Kinzler K.W., et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7 (2005) 561-573
97. Sancak Y., Thoreen C.C., Peterson T.R., Lindquist R.A., Kang S.A., Spooner E., Carr S.A., and Sabatini D.M. PRAS40 Is an Insulin-Regulated Inhibitor of the mTORC1 Protein Kinase. Mol. Cell 25 (2007) 903-915
98. Sarbassov D., Ali S.M., and Sabatini D.M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17 (2005) 596-603
99. Sarbassov D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., and Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22 (2006) 159-168
100. Sarbassov D., and Sabatini D.M. Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J. Biol. Chem. 280 (2005) 39505-39509
101. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., and Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14 (2004) 1296-1302
102. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
103. Schalm S.S., Fingar D.C., Sabatini D.M., and Blenis J. TOS Motif-Mediated Raptor Binding Regulates 4E-BP1 Multisite Phosphorylation and Function. Curr. Biol. 13 (2003) 797-806
104. Schroder W., Cloonan N., Bushell G., and Sculley T. Alternative polyadenylation and splicing of mRNAs transcribed from the human Sin1 gene. Gene 339 (2004) 17-23
105. Schroder W.A., Buck M., Cloonan N., Hancock J.F., Suhrbier A., Sculley T., and Bushell G. Human Sin1 contains Ras-binding and pleckstrin homology domains and suppresses Ras signallling. Cell. Signal. (2007) in press
106. Sekulic A., Hudson C.C., Homme J.L., Yin P., Otterness D.M., Karnitz L.M., and Abraham R.T. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60 (2000) 3504-3513
107. Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., and Cantley L.C. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6 (2004) 91-99
108. Shiota C., Woo J.T., Lindner J., Shelton K.D., and Magnuson M.A. Multiallelic Disruption of the rictor Gene in Mice Reveals that mTOR Complex 2 Is Essential for Fetal Growth and Viability. Dev. Cell 11 (2006) 583-589
109. Skeen J.E., Bhaskar P.T., Chen C.C., Chen W.S., Peng X.D., Nogueira V., Hahn-Windgassen A., Kiyokawa H., and Hay N. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 10 (2006) 269-280
110. Smith E.M., Finn S.G., Tee A.R., Browne G.J., and Proud C.G. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J. Biol. Chem. 280 (2005) 18717-18727
111. Sodhi A., Chaisuparat R., Hu J., Ramsdell A.K., Manning B.D., Sausville E.A., Sawai E.T., Molinolo A., Gutkind J.S., and Montaner S. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 10 (2006) 133-143
112. Sodhi A., Montaner S., Patel V., Gomez-Roman J.J., Li Y., Sausville E.A., Sawai E.T., and Gutkind J.S. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc. Natl. Acad. Sci. USA 101 (2004) 4821-4826
113. Stallone G., Schena A., Infante B., Di Paolo S., Loverre A., Maggio G., Ranieri E., Gesualdo L., Schena F.P., and Grandaliano G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 352 (2005) 1317-1323
114. Staveley B.E., Ruel L., Jin J., Stambolic V., Mastronardi F.G., Heitzler P., Woodgett J.R., and Manoukian A.S. Genetic analysis of protein kinase B (AKT) in Drosophila. Curr. Biol. 8 (1998) 599-602
115. Suzuki A., de la Pompa J.L., Stambolic V., Elia A.J., Sasaki T., del Barco Barrantes I., Ho A., Wakeham A., Itie A., Khoo W., et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8 (1998) 1169-1178
116. Tavazoie S.F., Alvarez V.A., Ridenour D.A., Kwiatkowski D.J., and Sabatini B.L. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat. Neurosci. 8 (2005) 1727-1734
117. Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., Czernin J., and Sawyers C.L. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12 (2006) 122-127
118. Tirado O.M., Mateo-Lozano S., Sanders S., Dettin L.E., and Notario V. The PCPH oncoprotein antagonizes the proapoptotic role of the mammalian target of rapamycin in the response of normal fibroblasts to ionizing radiation. Cancer Res. 63 (2003) 6290-6298
119. Tothova Z., Kollipara R., Huntly B.J., Lee B.H., Castrillon D.H., Cullen D.E., McDowell E.P., Lazo-Kallanian S., Williams I.R., Sears C., et al. FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress. Cell 128 (2007) 325-339
120. Um S.H., Frigerio F., Watanabe M., Picard F., Joaquin M., Sticker M., Fumagalli S., Allegrini P.R., Kozma S.C., Auwerx J., and Thomas G. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431 (2004) 200-205
121. Urano J., Comiso M.J., Guo L., Aspuria P.J., Deniskin R., Tabancay Jr. A.P., Kato-Stankiewicz J., and Tamanoi F. Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, Rheb, in fission yeast. Mol. Microbiol. 58 (2005) 1074-1086
122. Uritani M., Hidaka H., Hotta Y., Ueno M., Ushimaru T., and Toda T. Fission yeast Tor2 links nitrogen signals to cell proliferation and acts downstream of the Rheb GTPase. Genes Cells 11 (2006) 1367-1379
123. Wan X., Harkavy B., Shen N., Grohar P., and Helman L.J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26 (2007) 1932-1940 10.1038/sj.onc.1209990 Published online September 25, 2006
124. Wang H., Kubica N., Ellisen L.W., Jefferson L.S., and Kimball S.R. Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J. Biol. Chem. 281 (2006) 39128-39134
125. Williams M.E., and Densmore J.J. Biology and therapy of mantle cell lymphoma. Curr. Opin. Oncol. 17 (2005) 425-431
126. Withers D.J., Ouwens D.M., Nave B.T., van der Zon G.C., Alarcon C.M., Cardenas M.E., Heitman J., Maassen J.A., and Shepherd P.R. Expression, enzyme activity, and subcellular localization of mammalian target of rapamycin in insulin-responsive cells. Biochem. Biophys. Res. Commun. 241 (1997) 704-709
127. Witzig T.E., Geyer S.M., Ghobrial I., Inwards D.J., Fonseca R., Kurtin P., Ansell S.M., Luyun R., Flynn P.J., Morton R.F., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 23 (2005) 5347-5356
128. Witzig T.E., and Kaufmann S.H. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr. Treat. Options Oncol. 7 (2006) 285-294
129. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
130. Yang Q., Inoki K., Ikenoue T., and Guan K.L. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 20 (2006) 2820-2832
131. Yang Z.Z., Tschopp O., Di-Poi N., Bruder E., Baudry A., Dummler B., Wahli W., and Hemmings B.A. Dosage-dependent effects of Akt1/protein kinase Balpha (PKBalpha) and Akt3/PKBgamma on thymus, skin, and cardiovascular and nervous system development in mice. Mol. Cell. Biol. 25 (2005) 10407-10418
132. Yang Z.Z., Tschopp O., Hemmings-Mieszczak M., Feng J., Brodbeck D., Perentes E., and Hemmings B.A. Protein kinase B alpha/Akt1 regulates placental development and fetal growth. J. Biol. Chem. 278 (2003) 32124-32131
133. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H., and Morrison S.J. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 (2006) 475-482
134. Yokogami K., Wakisaka S., Avruch J., and Reeves S.A. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr. Biol. 10 (2000) 47-50
135. Zeng Z., Sarbassov D.D., Samudio I.J., Yee K.W., Munsell M.F., Jackson C.E., Giles F.J., Sabatini D.M., Andreeff M., and Konopleva M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109 (2007) 3509-3512 10.1182/blood-2006-06-030833 Published online December 19, 2006
136. Zhang H., Bajraszewski N., Wu E., Wang H., Moseman A.P., Dabora S.L., Griffin J.D., and Kwiatkowski D.J. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest. 117 (2007) 730-738
137. Zhang H.H., Lipovsky A.I., Dibble C.C., Sahin M., and Manning B.D. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol. Cell 24 (2006) 185-197
138. Zick Y. Ser/Thr phosphorylation of IRS proteins: A molecular basis for insulin resistance. Sci. STKE 2005 (2005) pe4